Risk-based and diagnostics-linked personalized medicine for cancer.
作者信息
Srivastava Sudhir, Wagner Paul D
机构信息
Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, Suite 3142, Rockville, MD 20892, USA.
出版信息
Per Med. 2007 Feb;4(1):33-43. doi: 10.2217/17410541.4.1.33.
Personalized medicine is gaining momentum in healthcare by allowing physicians to determine an individual's predisposition to different diseases and to better diagnose and treat those diseases. Personalized medicine is frequently described as the right drug for the right patient at the right time; that is, a physician will prescribe treatment based on the individual characteristics of each patient such that the patient is likely to respond to a particular treatment with minimal adverse events. The heterogeneity of cancer makes the implementation of personalized medicine a necessity.
Zotero 插件